Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

80.60 +15.84 (+24.46%)
Streaming Delayed Price Updated: 2:15 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,809,473
Open 75.29
Bid (Size) 80.59 (4)
Ask (Size) 80.77 (4)
Prev. Close 64.76
Today's Range 75.00 - 84.89
52wk Range 45.50 - 76.11
Shares Outstanding 94,324,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. 
Via Benzinga

Performance

YTD
+14.35%
+14.35%
1 Month
+23.30%
+23.30%
3 Month
+19.46%
+19.46%
6 Month
+46.60%
+46.60%
1 Year
+27.58%
+27.58%

More News

Read More
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Climbs to New 52-Week High
Via Investor Brand Network
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
Via Investor's Business Daily
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Expert Ratings for Intra-Cellular Therapies
Via Benzinga
Intra-Cellular Therapies's Earnings: A Preview
Via Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Are These Biotechs Ready To Launch?
Via Talk Markets
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
Via Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
Via Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.